Arcellx

Arcellx is a clinical-stage biotechnology company that develops novel chimeric antigen receptor cellular therapies for cancers and autoimmune diseases. The enterprise engineers synthetic D-Domain binders that replace traditional single-chain variable fragments, creating CAR-T therapies with high binding avidity and low immunogenicity like anito-cel for relapsed multiple myeloma. Through collaborative development with Kite Pharma, Arcellx aims to deliver safer and more accessible cell therapies to oncology patients.